insulin degludec + liraglutide

insulin degludec + liraglutide is a fixed-ratio combination injectable drug composed of two active ingredients: insulin degludec (a long-acting basal insulin analog) and liraglutide (a glucagon-like peptide 1 receptor agonist). This combination provides dual mechanisms for glycemic control in adults with type 2 diabetes mellitus whose blood glucose is inadequately controlled on oral antidiabetic drugs or basal insulin alone. Insulin degludec lowers fasting plasma glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production via activation of the insulin receptor. Liraglutide acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, delaying gastric emptying, and reducing appetite. The two components act synergistically to improve glycemic control while minimizing the risk of hypoglycemia and weight gain compared to basal insulin alone. The product is administered once daily by subcutaneous injection[1][2][3][4][5][6].

Brand names

Xultophy诺和益

Other names

德谷胰岛素利拉鲁肽注射液Insulin Degludec and Liraglutide Injection